Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GNE-7915是一种高效选择性,可渗透大脑的,富含亮氨酸的重复激酶 2 (LRRK2) 抑制剂,IC50值为9 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 185 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 743 | 现货 | ||
25 mg | ¥ 1,430 | 现货 | ||
50 mg | ¥ 2,450 | 现货 | ||
100 mg | ¥ 3,990 | 现货 | ||
200 mg | ¥ 5,270 | 现货 | ||
500 mg | ¥ 8,190 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor. |
靶点活性 | LRRK2:1 nM(Ki), LRRK2:9 nM |
体外活性 | 表达人LRRK2蛋白质且携带G2019S帕金森病突变体的BAC转基因小鼠,腹腔注射或口服50 mg/kg GNE-7915导致大脑中pLRRK2的浓度依赖性基因沉默.GNE-7915在大鼠体内,表现出良好的PK性能,具有较长的半衰期,良好的口服利用率和高被动渗透性. |
体内活性 | GNE-7915在人肝细胞中表现出极好的体外药代动力学,转换率最小。根据体外功能测试,GNE-7915也是中等有效的5-HT2B拮抗剂。 |
激酶实验 | ALK2 kinase assay: Puri?ed recombinant ALK2 proteins, ATP, ATP[γ-32P], and dephosphorylated casein at ?nal concentrations of 2.5 nM, 6 μM, 0.05 μCi/μL , and 0.5 mg/mL, respectively, are aliquoted in kinase bu?er containing 0.2% BSA supplemented with 10 mM MnCl2 into 96-microwell plates, in combination with inhibitor compounds diluted at varying concentrations (0.01 nM to 100 μM). Positive control samples lacking inhibitor compounds, and negative controls lacking recombinant kinase, are also measured. The mixture is reacted at RT for 45 min, quenched with a ?nal concentration of 2% phosphoric acid. The reaction mixture is transferred to 96-well P81 phosphocellulose ?lter plates and bound for 5 min. The plates are washed 20 times with 150 μL of 1% phosphoric acid solution per well by vacuum manifold. Plates are dried at RT for 1 h, sealed, and assayed with Microscint 20 scintillation ?uid using a Spectramax L luminometer. Data is normalized to positive controls at 100% enzyme activity, with negative controls being subtracted as background. |
别名 | GNE7915 |
分子量 | 443.4 |
分子式 | C19H21F4N5O3 |
CAS No. | 1351761-44-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 21 mg/mL (47.4 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2553 mL | 11.2765 mL | 22.553 mL | 56.3825 mL |
5 mM | 0.4511 mL | 2.2553 mL | 4.5106 mL | 11.2765 mL | |
10 mM | 0.2255 mL | 1.1276 mL | 2.2553 mL | 5.6382 mL | |
20 mM | 0.1128 mL | 0.5638 mL | 1.1276 mL | 2.8191 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GNE-7915 1351761-44-8 Autophagy LRRK2 inhibit Inhibitor GNE 7915 Leucine-rich repeat kinase 2 GNE7915 inhibitor